AU3873400A - Docusate hard gelatin capsules - Google Patents

Description

WO 00/67747 PCT/USOO/06200 DOCUSATE HARD GELATIN CAPSULES Field of the Invention 5 The present invention relates to a formulation comprising bis(2-ethylhexyl)sulfosuccinate, which can be readily filled into hard capsules, and liquid-filled hard capsules containing said formulation. 10 Background of the Invention Hard capsules have traditionally been used as a container for particulate solids that are usually in the form of powders or 15 pellets. For drugs either dissolved or suspended in a liquid vehicle for a long time the only available oral unit dosage form was the soft capsule. However, formulating drug substances such as liquids for 20 filling into hard capsules offers various benefits. For example, the filling of liquids into capsules presents no dust hazard and the possibility of cross-contamination via airborne particles can also be eliminated. 25 Furthermore, the excipient used provides protection against moisture and oxygen by totally surrounding the drug particles thus improving the formulation of oxygen-sensitive or moisture-sensitive drugs and extending their shelf life. 30 In general, the excipients to be used for formulations of liquid fill hard capsules may be classified according to rheological properties during the filling stage. Liquid- WO00/67747 PCT/US00/06200 filled formulations can be (a) mobile Newtonian liquids, (b) thixotropic gels both fillable at ambient temperature and (c) thermosoftening systems which are either Newtonian or non Newtonian at elevated filling temperatures, e.g. 70 0 C, but 5 solid at ambient temperature. Satisfactory filling, however, requires that the active ingredient can be dissolved or melted in the excipient at least at the filling temperature, as problems associated with 10 drug dispersion, content uniformity and filling could arise if the active ingredient remains as solid phase at the maximum acceptable filling temperature for hard capsules of 70 oC. 15 Summary of the Invention According to the present invention it has surprisingly been found that bis(2-ethylhexyl)-sulfosuccinate (melting point of bis(2-ethylhexyl)sulfosuccinate sodium is in a range of from 20 153 to 157 0 C according to the Handbook of Pharmaceutical Excipients, second edition, Ed. Wade, Ainley and Weller, Paul J., 1994, page 173)can be successfully dissolved in specific excipients to produce a formulation suitable for liquid filling into hard capsules due to the fact that the 25 formulation forms a solution at least at the maximum acceptable liquid-filling temperature for hard capsules. According to the first aspect, the present invention provides a formulation comprising bis(2-ethylhexyl)sulfosuccinate and 30 an excipient selected from the group consisting of glyceride derivatives, polyethylene glycols and mixtures thereof, which formulation forms a solution at least at the maximum 2 WO00/67747 PCT/USOO/06200 acceptable liquid-filling temperature for hard capsules. According to a second aspect there is provided a method for preparing such a formulation by mixing bis(2 5 ethylhexyl)sulfosuccinate and an excipient selected from the group consisting of glyceride derivatives, polyethylene glycols and mixtures thereof, with stirring, and optionally heating the mixture at elevated temperatures in order to form a formulation which forms a solution at least at the maximum 10 acceptable liquid-filling temperature for hard capsules. According to a third aspect there are provided liquid-filled hard capsules comprising such a formulation. 15 According to a forth aspect there is provided a method for preparing liquid-filled hard capsules comprising the following steps: a) filling a formulation comprising bis(2 20 ethylhexyl)sulfosuccinate and an excipient selected from the group consisting of glyceride derivatives, polyethylene glycols and mixtures thereof, in a liquid state into the capsule body; b) closing the capsule body with a cap component; and 25 optionally c) sealing the capsule using the water/ethanol microspray technique. Further preferred embodiments are described in the detailed 30 description below. Detailed Description of the Present Invention 3 WO00/67747 PCT/US00/06200 The empty hard capsule is composed of shell material, water and, optionally, colouring and/or opacifying agents. The shell material may be selected from gelatin, cellulose 5 ethers, starch or polyvinylalcohol or mixtures thereof. Gelatin may be of animal or non-animal origin or of modified gelatins like succinylated gelatin. Suitable cellulose ethers are alkyl- and/or hydroxyalkyl substituted cellulose ether with 1 to 4 carbon atoms in the alkyl chains, 10 preferably methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethylmethyl cellulose, hydroxyethylethyl cellulose, hydroxypropylmethyl cellulose or the like. Starch may be e.g. corn starch or modified starches such as starch ethers and oxidized starch, more 15 particularly hydroxpropylated starch and hydroxyethylated starch. Hereby the empty hard capsule is a container of stable dimensions. The capsule shells can be standard articles available on the market from industrial suppliers, for 20 example, the Capsugel Division of the Warner-Lambert Company, the European Hard Capsule Division of R.P. Scherer, or Shionogi Company. Empty capsules are robust and show good stability on storage 25 in a wide range of conditions. When stored in their original containers at for example 15 to 20 0 C and 35 to 65% relative humidity, they form a suitable delivery route for many drug formulations. Because of their stability, according to the present invention hard capsules can be successfully filled 30 and used in all countries with climates rating from arctic to tropical. 4 WO00/67747 PCT/USOO/06200 One essential component of the formulations according to the present invention is bis(2-ethylhexyl)sulfosuccinate (which is often also called "docusate"), more preferred bis(2 ethylhexyl)sulfosuccinate sodium, bis(2 5 ethylhexyl)sulfosuccinate potassium or bis(2 ethylhexyl)sulfosuccinate calcium, most preferred bis(2 ethylhexyl)sulfosuccinate sodium. Bis(2-ethylhexyl)sulfosuccinate ("docusate") is widely used 10 in pharmaceutical formulations as an anionic surfactant, wetting agent as well as laxative and fecal softener. Therefore, the formulations according to the present invention could be used in several different ways, for example as a laxative composition or as a basic formulation 15 of hard capsules, which offers the possibility to produce formulations containing other active ingredients which formulations remain in a stable and clear state over a prolonged period of time. 20 According to the present invention the content of bis(2 ethylhexyl)sulfosuccinate based on the total weight of the liquid fill, is usually in a range of from 0.01 to 99,99 % w/w, preferably in a range of from 0,1 to 90 % w/w, more preferably in a range of from 1 to 80 % w/w and most 25 preferably in a range of 5 to 50 % w/w. According to the present invention, the excipients used are selected from glyceride derivatives, polyethylene glycols and mixtures thereof. In a preferred embodiment of the first 30 aspect of the present invention the excipient selected is a thermosoftening excipient selected from the above-mentioned group. 5 WO00/67747 PCT/US00/06200 Preferably, the polyethylene glycols used according to the present invention have melting ranges from 40 to 70 0 C and are available in a wide range of viscosity grades. The 5 polyethylene gly-cols, especially polyethylene glycols, usually have a weight average molecular weight in a range of from 1000 to 20000, preferably in a range of from 2000 to 10000, more preferably in a range of from 3000 to 6000 and most preferably have a weight average molecular weight of 10 6000. There also can be used polyethylenglycol/polypropylengly-col copolymers which are often also called poloxamers. Polyethylene glycols having average molecular weight grades 15 below 1000 for example are hygroscopic so they tend to dehydrate and crack capsule shells. Viscosity grades above 20000 tend to produce matrices that sometimes craze on cooling, and thus, may give a less elegant matrix appearance and unexpectedly high matrix viscosities in the process. 20 Glyceride derivatives include semi-synthetic glycerides and chemical glycerides and are preferably characterized by melting-point ranges of 30 to 60 0 C and by varying degrees of hydrophilicity (HLB values between 2 and 20). These 25 materials may be selected according to the melting range and HLB value to provide a wide range of release-rate characteristics. Usable semi-synthetic glycerides comprise medium-chain 30 partial glycerides with varying melting ranges and HLB values according to their content of mono-diglycerides and the chain length of the specific fatty acid concerned. 6 WO00/67747 PCTIUS00/06200 Usable chemical glycerides are excipients derived from vegetable oils, preferably hydrogenated vegetable oils. These compounds are defined as saturated poly(glycol) 5 glycerides and contain varying blends of glycerides (mono ,di- and tri) and their mono- and di-esters, plus polyethylene glycols and low-molecular weight polyethylene glycols. 10 In general, the excipient used should have physical characteristics which enable the fill material to be satisfactorily dosed, without stringing, between room temperature and about 700C. The upper limit of 70 0 C is the maximum acceptable temperature for the shell capsule. 15 In general, the excipient used should have a viscosity ranging from 0.1 Pa s to 27 Pa s at room temperature. More preferred excipients to be used according to the present 20 invention are excipients derived from hydrogenated fat and oils with controlled hydrophilic properties, such as excipients available under the trademark Gelucire, polyethylene glycols having weight average molecular weight ranges of 3000 to 6000, available as PEG-3000 to PEG-6000, 25 myristic acid triglycerides, available under the trademark Dynasan, other suitable vegetable oil excipients such as Miglyol 812 N, Miglyol 829, arachis (peanut), sesame, corn and cottonseed oil; and polyethylene glycol/polypropylene glycol-copolymers, usually designated as poloxamers. 30 In addition, besides excipients and active ingredients, the liquid fill formulations may contain other components which 7 WO00/67747 PCT/US00/06200 are usually included into liquid-filled formulations. Examples of these components comprise adjuvants, colouring agents, viscosity changing components, softening agents, 5 thickening agents, diluents, opacifying agents and other components. Preferred additives are thickening agents such as silicon dioxides, partial glycerides, for example mixtures of mono 10 and diglycerides, glycol stearates, waxy ester materials, glyceryl stearates, cetyl palmitate, polyoxyalkylene glycerol monostearate waxes, fatty acid mixtures, glycerine monostearates, hydrated castor oil, mixtures of mono diglycerides of higher saturated fatty acids, mixtures of 15 fatty alcohols, waxes and oils, mixtures of mono- and diglycerides of palmitinic and stearic acid, and fatty alcohol ether sulfates. Such additives are available on the market for example under the trademark Aerosil from Degussa, UK, CutinaR AGS, CutinaRBW, CutinaR CP, Cutina CP-A, Cutina 20 E24, Cutina EGMS, Cutina FS25, CutinaR GMS, CutinaR HR, CutinaR KD16, Cutina LE, CutinaRLM, Cutina R MD, Cutina MD-A and Cutina TS. At present, as a preferred thickening agent, silicon dioxide 25 is used. According to the present invention it has been found that dispersion of silicon dioxide in formulations containing an oil excipient selected from the group consisting of glyceride 30 derivatives, polyethylene glycols and mixtures thereof, preferably glyceride derivatives, especially vegetable oils, to produce a clear and stable gel having an increased 8 WO00/67747 PCT/US00/06200 viscosity, can be simplified if the formulation also includes bis(2-ethylhexyl)sulfosuccinate. In general, it is advisable to disperse silicon dioxide into 5 excipients, such as glycerides, for example Miglyol 812, in order to increase the viscosity of the excipient. Hereby, it is necessary to produce a gel having suitable properties for filling into hard capsules without spillage during the filling step which can result in unsealed and leaking 10 capsules. Usually, the dispersion of silicon dioxide, however, is a very difficult process requiring a lot of energy and time. In addition, a large amount of air can become incorporated into the dispersion making a deaeration step under vacuum necessary. 15 According to the present invention it was surprisingly found that if bis(2-ethylhexyl)sulfosuccinate is added to an oil excipient selected from the group consisting of glyceride derivatives, polyethylene glycols and mixtures thereof, the 20 production of a gelified oil system is much easier, taking only a few minutes, requiring only gentle stirring and with little entrapment of air. Such a system is very suitable for filling into hard capsules. 25 The method for preparing liquid-filled hard capsules will be described below: In a first step bis(2-ethylhexyl)sulfosuccinate and the excipient as well as one or more additives mentioned above 30 are combined to form a mixture. If the excipient is a liquid at ambient temperature, bis(2-ethylhexyl)sulfo-succinate can be dissolved or dispersed in the excipient. If a suspension 9 WO00/67747 PCTIUS00/06200 is to be produced at room temperature, the particle size of the drug must not exceed 100 gm and the consistency of the vehicle must be sufficient to prevent sedimentation. Solvents such as glycerol, propylene glycol and sorbitol 5 which are commonly used in syrups and soft shell capsules, are hygroscopic and are unsuitable as excipients for filling into hard capsules. This also applies to PEGs having a molecular weight of less than 1000. These PEGs are too hygroscopic and therefore not recommended for filling into 10 hard capsules at high concentrations. According to a preferred embodiment of the present invention, thermosoftened materials are used as the excipients. 15 In general, the thermosoftening material selected is non toxic, pharmacologically inert and the melting point is low enough so that thermal damage to the capsule body or degradation of bis(2-ethylhexyl)sulfosuccinate is avoided. Furthermore, it is preferred that the melting point is high 20 enough to prevent melting during transportation and storage. In general, bis(2-ethylhexyl)sulfosuccinate can be formulated with an excipient used according to the present invention either at room temperature or at elevated temperatures to 25 form a fluid. The manufacturing process comprises liquefying an excipient (this means a melting step if thermosoftening excipients are used, or a simple stirring step when using liquids), adding bis(2-ethylhexyl)sulfosuccinate into the liquefied excipient, and optionally heating the resulting 30 mixture to obtain a composition which forms a solution at least at the maximum acceptable liquid-filling temperature for hard shell. 10 WO00/67747 PCT/USOO/06200 In general, thermosoftening excipients are selected according to narrow melting ranges within the region of 30 to 600C and also so as to match the requirements on viscosity to ensure 5 good filling control. Increasing the viscosity of the filling composition, for example, can be achieved by adding a thickening agent, for example one of the additives mentioned above, especially 10 silicon dioxide. According to the second aspect of the present invention, there is provided a method for preparing a formulation suitable for liquid-filling into hard capsules by mixing 15 bis(2-ethylhexyl)sulfosuccinate and an excipient selected from the group consisting of glyceride derivatives, polyethylene glycols and mixtures thereof, with stirring, and optionally heating the mixture at elevated temperatures in order to form a formulation which forms a solution at least 20 at the maximum acceptable liquid-filling temperature for hard capsules. The excipients used are preferably middle chain length vegetable fatty acid esters, such as Miglyol® oils, polyethylene glycols, such as PEG 6000, and poloxamers such as polyoxamers of the Synperonic® series. 25 In a preferred embodiment of the present invention the formulation comprising bis(2-ethylhexyl)sulfosuccinate and an excipient as defined above, also includes silicon dioxide as a thickening agent in order to increase viscosity and to 30 maintain clarity of the gel produced. Hereby, silicon dioxide can be added to the mixture of bis(2 11 WO00/67747 PCTIUS00/06200 ethylhexyl)sulfosuccinate and the excipient used according to the present invention. To improve the dissolution or dispersion of the active 5 ingredient and/or the additive(s) in the excipient, the mixture can be subjected to a mechanical mixing for example by using a magnetic stirring device, for example a paddle mixer, or by sonification, such as an ultrasonic method. 10 According to the present invention it has been found that an ultrasonic method decreases the time for dissolution or dispersion. However, sometimes the increase in water temperature due to ultrasonic vibration was not easily controllable, so mechanical stirring is the preferred measure 15 to improve the dissolution or dispersion of the active ingredient. In general, bis(2-ethylhexyl)sulfosuccinate is a waxy solid which is difficult to disperse or even to dissolve in liquids 20 or molten excipients because of its cohesive texture. For example, poloxamers are more effective dispersion vehicles in the molten state for bis(2-ethylhexyl)sulfosucci-nate than polyethylene glycols. Thus, for ambient filling it is preferred to effect solution of bis(2 25 ethylhexyl)sulfosuccinate in a liquid excipient. This can be achieved by using one of the glycerides defined above at room temperature or at elevated temperature (for example 30 to 50 0 C) depending on the oil properties and mixing conditions. 30 Thus, the temperature for dissolution could preferably be in a range of 30 to 500C in case of vegetable oil excipients optionally by using magnetic stirring, in a range of 80 to 12 WO00/67747 PCTIUS00/06200 110 oC (especially 100 0 C) optionally by using magnetic stirring, if PEG, for example PEG 6000, is used, in a range of 50 to 70 OC in case of a semi-solid or solid poloxamer is used and at room temperature to 40 0 C, preferably in a range 5 of from 30 to 40 0 C optionally by using magnetic stirring, if a liquid poloxamer excipient is used. If a solution of bis(2-ethylhexyl)sulfosuccinate and the excipient has been formed, such a solution will be reformed even in the case of thermosoftening excipients at least at the maximum filling 10 temperature of the hard capsules. Additionally, exposition to oxygen of the formulation in some cases could be disadvantageous. Therefore, according to the present invention mixing will be usually carried out without 15 aeration of the formulation. A further important factor is the size of bis(2 ethylhexyl)sulfosuccinate used during mixing. To improve the mixing of bis(2-ethylhexyl)sulfosuccinate in the excipient 20 the size of bis(2-ethylhexyl)sulfosuccinate could be reduced for example by grating, in order to facilitate mixing, dispersion and/or dissolution. In a second step the capsule body is filled with the liquid 25 mixture, for example in a highspeed machinery, which involves pumping of the formulation through precision pumps to ensure good filling weight uniformity throughout processing. In order to optimize filling weight uniformity particle size distribution, proportion of solids content and processing 30 temperature have to be considered. Of further interest is the behaviour of the excipient not 13 WO00/67747 PCTUS00/06200 only immediately after preparation but also on prolonged processing. Thermosoftening excipients used must be able to withstand 5 prolonged high temperature exposure without significant physical or chemical change. Regarding the capsule filling machines, most modern capsule filling machines can be modified to allow hard gelatin 10 capsules to be filled with liquid in either a cold or hot state. In general, there are five recommended requirements for liquid- filling machines. Firstly, they should maintain the product at a constant temperature of up to about 700C. Secondly, they should maintain a homogenous suspension in a 15 product hopper. Thirdly, the machine should accurately dose volumes of liquid from 0.001 to 10 ml. Fourthly, they should eject a filled capsule body when the cap is missing. Fifthly, they should interrupt dosing when a capsule body is absent. 20 In a third step the capsule body is closed by a cap. If capsules are filled with materials that remain fluid, these capsules require sealing to prevent leakage. Sealing also prevents ingress of oxygen and can improve stability. 25 There are various methods used in the art to hermetically seal hard gelatin capsules. For example, there is a method which involves spraying the 30 filled capsule with water and an alcohol mixture. The low surface tension of this liquid allows rapid penetration between the body and cap of the capsule. During a warming 14 WO00/67747 PCT/USOO/06200 step, the gelatin in the overlapping zone is melted and the capsule body and cap are fused together. See for example EP A-0 180 543 which is enclosed herewith for reference. 5 As a second method for sealing capsules, a process can be used which involves passing the capsule over a wheel that revolves in a gelatin bath. A quantity of gelatin is picked up by the wheel and deposited on the junction between the body and the cap. The gelatin band is dried by passing the 10 capsule through a drying chamber. As a third method, a method of sealing a hard gelatin capsule may be mentioned, wherein a gelatin band is applied to the junction between the body and cap of the capsule. 15 Bis(2-ethylhexyl)sulfosuccinate, which is also called docusate, can be used as a laxative to provide stimulant and softening properties. The docusate used is usually docusate sodium, however also docusate calcium and docusate potassium 20 could be used according to the present invention. According to a further embodiment of the present invention capsules are further provided containing a formulation as defined above. These capsules can be used to orally 25 administer bis(2-ethylhexyl)sulfosuccinate in a very safe manner. Furthermore, the capsules prepared show a very high stability of the formulation contained. According to a further embodiment of the present invention 30 there is provided a method of treating subjects including human beings suffering from obstruction by orally administering liquid fill hard gelatin capsules containing 15 WO00/67747 PCTUS00/06200 bis(2-ethylhexyl)sulfosuccinate. Examples 5 The following examples should not be construed as limiting the present invention in any way but only to further illustrate the present invention as defined by the appended claims. 10 Example 1 Six types of vegetable oil excipients were studied as the solvents for bis(2-ethylhexyl)sodium sulfosuccinate (DS), and these were Miglyol 812N, Miglyol 829, Arachis (Peanut), Sesame, Corn and Cottonseed oil. 15 Preliminary experiments on small batches were undertaken to investigate the solubility of DS in the liquid vehicles using (a) ultrasonics and (b) magnetic stirring. 20 The ultrasonic method decreased the time for dissolution of DS in the oil excipients, however, the increase in water temperature due to ultrasonic vibration, was not controllable and therefore considered not totally suitable for manufacture. The time for dissolution of the same 25 concentration of DS in the formulation decreased considerably at 45 0 C in comparison with 37 0 C using magnetic stirring. Three concentrations of DS with the different vegetable oil excipients were prepared according to the volume of capsule 30 size 1, i.e. 100 mgDS/350 mg excipient, 100mgDS/400mg excipient and 100mgDS/500mg excipient. The solutions obtained with DS/Miglyol 812N and DS/Miglyol 829 in the three 16 WO00/67747 PCT/US00/06200 concentrations were all clear and stable, whereas the only clear solution of DS with cottonseed oil when stored at room temperature was 100mgDS/500mg Cottonseed. The remaining DS solutions prepared with the other vegetable oil excipients 5 showed evidence of crystallization of DS after 24 hours at room temperature so that heating was necessary to obtain clear solutions. Solution of DS in Miglyol 812N can also be achieved at room temperature with overnight storage. 10 Finally, the formulations with the concentrations of 100mgDS/350mgMiglyol 812N and 100mgDS/350mgMiglyol 829 were selected to produce the 500g batch for the compatibility test. 15 Example 2 Cutina HR was suggested as an additive agent for changing the viscosity of DS formulation with Miglyol 812N. Previous investigations had used silicon dioxide to change the viscosity and maintain clarity of the gel. 20 The viscosity of the formulation of 100mg DS/350mg Miglyol 812N was increased by increasing the concentration of Cutina from 1% to 5%w/w. A series of experiments was carried out to investigate the effect of temperature on gel formation from 25 room temperature to 450C, with the formulation of 100mg DS/350mg Miglyol812N/l% Cutina. As a result, all formulations provided stable solutions, which in the case of cutina were not transparent. 30 Example 3 A normal oral dose of DS is a 100mg/capsule and thus a formulation containing 20% w/w DS in polymer was investigated 17 WO00/67747 PCT/USOO/06200 (capsule fill weight of 500 mg). From the thermal characteristics it was assumed that this formulation could be filled on the second heating cycle at the normal capsule filling temperature of 70 0 C. However, the first heating 5 cycle for the preparation of the drug formulation with PEG 6000 required investigation using three different physical thermal mixing methods in order to determine the best conditions for drug dispersion in the molten polymer prior to filling. The best dispersion of DS in PEG 6000 was achieved 10 by dispersing solid DS in melted PEG 6000 in an oven at 1000C with mixing by a magnetic stirrer. Recent results with poloxamer PE/F68 indicate much easier dissolution of DS than with PEG 6000. 15 Example 4 Two liquid Synperonic excipients and three pharmaceutical grade Synperonic excipients were used in the development of formulations of DS/poloxamers. DS was successfully dissolved in Synperonic PE/L61, PE/L81, PE/F68, PE/F87 and PE/F108. 20 The concentrations of DS with poloxamer chosen for a size 1 capsule were 100mg DS/350mg Synperonic PE/L- and 100mg DS/400mg Synperonic PE/F-. For the liquid formulations of DS/poloxamer matrixes, it was 25 found that the dispersion took 14 hours by using magnetic stirring at room temperature. In the same case, the dissolution only required 45 mins in the 37 0 C water bath with magnetic stirring after the DS/poloxamer mixture was kept at room temperature for 24 hours. The dispersion time was 30 affected by both the concentration of DS and the viscosity of the poloxamers. 18

Claims (10)

1. A formulation comprising bis(2-ethylhexyl)sulfosuccinate and an excipient selected from the group consisting of 5 glyceride derivatives, polyethylene glycols and mixtures thereof, which formulation forms a solution at least at the maximum acceptable liquid-filling temperature for hard capsules. 10

2. The formulation according to claim 1, wherein the excipient used is a polyethylene glycol having a weight average molecular weight of 2,000 to 10,000.

3. The formulation according to claim 2, wherein the 15 polyethylene glycol has a weight average molecular weight of 6,000.

4. The formulation according to claim 2, which also contains a thickening agent. 20

5. The formulation according to claim 4, wherein the thickening agent is silicon dioxide.

6. The formulation according to claim 1, wherein the 25 excipient used is a polyethylene glycol/polypropylene glycol copolymer (poloxamer).

7. A method for preparing a formulation suitable for liquid filling into hard capsules by mixing bis(2 30 ethylhexyl)sulfosuccinate and an excipient selected from the group consisting of glyceride derivatives, polyethylene glycols and mixtures thereof, with stirring, 19 WO00/67747 PCT/US00/06200 and optionally heating the mixture at elevated temperatures in order to form a formulation which forms a solution at least at the maximum acceptable liquid-filling temperature for hard capsules. 5

8. A liquid-filled hard capsule comprising a formulation as defined in claim 1.

9. A method for preparing liquid-filled hard capsules 10 comprising the following steps: a) filling a formulation comprising bis(2 ethylhexyl)sulfosuccinate and an excipient selected from the group consisting of glyceride derivatives, polyethylene glycols and mixtures thereof, which 15 formulation forms a solution at least at the maximum acceptable liquid-filling temperature for hard capsules, in a liquid state into the capsule body; b) closing the capsule body with a cap component; and optionally 20 c) sealing the capsule using the water/ethanol microspray technique.

10. A method for the treatment of obstruction in an animal including human beings suffering from said disease or 25 condition by administering a liquid-filled hard capsule according to claim 7. 20